Allopurinol News and Research

RSS

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout is a relatively common arthritic disease that affects about 4% (I in 25) of the population. It results from the deposition of uric acid in joints due to elevated blood levels and a resulting inflammation ensues which is very painful.

26 Jul 2013

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

The painful rheumatic condition gout is often associated with the big toe, but it turns out that patients at highest risk of further flare-ups are those whose gout first involved other joints, such as a knee or elbow, Mayo Clinic has found.

15 Jun 2013

Vitamin C and gout: an interview with Prof. Lisa Stamp

A previous study in by Choi et al in the USA showed that people with a higher vitamin C intake have a lower risk of gout. There are also studies in healthy volunteers that suggest that vitamin C supplements reduce blood uric acid levels.

4 Jun 2013

Research reveals vitamin C does not reduce urate levels in gout patients

Despite previous studies touting its benefit in moderating gout risk, new research reveals that vitamin C, also known ascorbic acid, does not reduce uric acid (urate) levels to a clinically significant degree in patients with established gout. Vitamin C supplementation, alone or in combination with allopurinol, appears to have a weak effect on lowering uric acid levels in gout patients according to the results published in the American College of Rheumatology (ACR) journal, Arthritis & Rheumatism.

17 May 2013

Allopurinol may improve CV outcomes in kidney disease

The xanthine oxidase inhibitor allopurinol appears to be beneficial in preventing cardiovascular morbidity and all-cause mortality in patients with hypertensive nephropathy, show findings from a Japanese study.

8 Feb 2013

Two-part ACR guidelines on gout

Gout is one of the most common forms of inflammatory arthritis, affecting nearly 4% of adult Americans. Newly approved guidelines that educate patients in effective methods to prevent gout attacks and provide physicians with recommended therapies for long-term management of this painful disease are published in Arthritis Care & Research, a peer-reviewed journal of the American College of Rheumatology (ACR).

28 Sep 2012

Cherry intake reduces risk of gout attacks

A new study found that patients with gout who consumed cherries over a two-day period showed a 35% lower risk of gout attacks compared to those who did not eat the fruit.

28 Sep 2012

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

BioCryst Pharmaceuticals, Inc. announced favorable 52-week safety results and sustained efficacy from the extension phase of its randomized Phase 2b trial of ulodesine (BCX4208) added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone, as well as positive Phase 2 safety results in patients with mild to moderate renal impairment.

25 Jul 2012

Steroids may slow progression of life-threatening skin reactions

Multi-national study results show that the progression of Steven Johnson Syndrome or Toxic Epidermal Necrolysis may be lengthened if corticosteroids are used prior to the onset of either condition.

8 Jun 2012

Risk of gout flare-ups greatly increased by purine rich foods

Foods rich in purines, particularly those found in meat and seafood, quintuple the immediate risk of a gout flare-up, finds research published online in the Annals of the Rheumatic Diseases.

31 May 2012

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos Corporation announced that it has successfully completed a proof-of-concept clinical trial using its compound levotofisopam (S-tofisopam) to treat patients with hyperuricemia and gout.

18 May 2012

BioCryst first quarter revenues increase to $12.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the first quarter ended March 31, 2012.

7 May 2012

BioCryst fourth quarter revenues decrease to $5.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

Rilonacept appears safe and well-tolerated in patients with gout

A phase II clinical trial found that rilonacept, an inhibitor of the protein interleukin-1 (IL-1), significantly reduced acute gout flares that occur when initiating uric acid-lowering therapy. Results of the trial—the first placebo-controlled study investigating IL-1 targeted therapy in prevention of gout flares—show rilonacept to be generally well tolerated with no serious infections or treatment-related serious adverse events reported.

5 Jan 2012

$Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL$

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, (NASDAQ: CELG), announced final results from a phase II investigational study evaluating the combination of REVLIMID® (lenalidomide) and rituximab in 59 patients with relapsed or refractory chronic lymphocytic leukemia (CLL). These data were presented at the 53rd Annual Meeting of the American Society of Hematology in San Diego, CA.

14 Dec 2011

Celgene announces interim results of REVLIMID study on CLL

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced interim results of CLL-009, a study evaluating three starting doses of REVLIMID (lenalidomide), followed by step-wise dose escalation as tolerated in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy.

12 Dec 2011

Positive results from Metabolex arhalofenate plus febuxostat study on hyperuricemia, gout

Metabolex announced positive results from its clinical study of arhalofenate in combination with febuxostat. A key goal in the treatment of gout is to address the patient's underlying hyperuricemia by treatment with drugs that lower serum uric acid.

9 Dec 2011

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.

22 Nov 2011